BioCentury
ARTICLE | Clinical News

Amicus gains on Amigal data

April 30, 2014 12:43 AM UTC

Amicus Therapeutics Inc. (NASDAQ:FOLD) was up $0.38 (21%) to $2.22 on Tuesday after reporting additional data from the Phase III FACETS trial (Study 011) of Amigal migalastat ( AT1001) to treat Fabry's disease. The new results showed Amigal met a revised primary endpoint in the study's second stage. Amigal previously missed a different primary endpoint in the study's first stage. ...